BioRestorative Therapies

06/05/2026

Francisco Silva is a translational leader with two decades of entrepreneurial and clinical-development experience in cell- and biologic-based therapeutics. As VP of Research at , he has led IND-enabling programs, secured fast-track designation, and served as principal investigator for multiple Phase II addressing degenerative disc disease.

Francisco has built and scaled cGMP manufacturing and QMS systems, forged successful collaborative research partnerships with Pfizer, UPenn, the University of Miami, and others, and holds multiple international patents in regenerative medicine, brown adipose–derived technologies, and 3D cell constructs. His peer-reviewed work spans metabolic, cardiac, and spinal applications, and he serves as Section Editor for the Regenerative Medicine section of the Journal of Translational Medicine.

Francisco combines hands-on scientific expertise with commercial strategy to advance next-generation and from bench to bedside.

06/03/2026

Skincare is getting smart. ’ biologic-powered products mix cutting-edge science with real cosmetic results. Learn how and growth factor-based formulations are changing the face of aesthetics.

Find out more: bit.ly/4sN69Rj

05/28/2026

Check out the latest episode of the Xtalks Webinars Life Sciences podcast, where ' CEO, Lance Alstodt, speaks to Dr. Ayesha Rashid about the evolving landscape of and the promise and challenges of stem cell-based therapies in treating chronic conditions like degenerative disc disease.

Listen to their full discussion here: https://www.youtube.com/watch?v=n_Z89oBe9DY&source_ve_path=MjM4NTE&embeds_referring_euri=https%3A%2F%2Fxtalks.com%2F

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Lance Alstodt, CEO, BioRe...

05/26/2026

announces that the last patient has been dosed in its fully enrolled Phase 2 evaluating BRTX-100 for the treatment of chronic lumbar disc disease, completing treatment administration in the Company’s lead clinical program and advancing the study into the next stage of blinded follow-up ahead of expected topline safety and efficacy data in Q2 2027.

Full press release here: https://bit.ly/4dxJoMf

05/21/2026

Chronic lower back pain remains one of the most persistent and costly challenges in global healthcare, affecting ~266 million people (3.63% of the global population) and over 30 million adults in the U.S. alone.

Patients report pain that significantly impacts their job, family obligations, ability to travel, and overall quality of life. Despite its prevalence, therapeutic innovation in this space has lagged behind other disease areas, such as oncology or genetic disorders.

' President and CEO, Lance Alstodt, shares how our team is working to redefine spine care through autologous in this Drug Delivery Leader byline article:

Autologous intradiscal therapy integrates delivery and biology into one system, highlighting the potential of cell therapies in complex, localized disease environments.

05/20/2026

Today is , an annual celebration and recognition of participants, researchers, and U.S. Food and Drug Administration staff who review and interpret results.

is proud of the progress being made across our ongoing as we work to utilize regenerative biology for longevity and healthier lives.

ACRP - Association of Clinical Research Professionals

05/15/2026

Today we’re featuring our exceptional Head of Global Commercialization, Crystal Romano.

A seasoned executive with two decades of progressive leadership in the medical, aesthetics, and regenerative industries, Crystal is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, and navigating patent and U.S. Food and Drug Administration regulations.

05/13/2026

announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy 2026 Annual Meeting.

This new data, presented by our Director of Research and Development, Michael Joyce, PhD, demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications.

Learn more: bit.ly/4354Hyt

05/08/2026

recently announced expanded blinded data from its fully enrolled Phase 2 evaluating BRTX-100. The data was presented at the Annual Meeting by our Chief Scientist, Francisco Silva.

The study’s efficacy criteria include at least a 30% decrease in pain and at least a 30% improvement in function at 52 weeks. The blinded ISCT dataset showed that a substantial portion of evaluable patients exceeded that threshold, achieving at least 50% improvement across key measures.

Learn more about the expanded blinded data as we advance toward the planned unblinding of our fully enrolled Phase 2 trial: https://ir.biorestorative.com/news-events/press-releases/detail/243/biorestorative-therapies-reports-expanded-phase-2-blinded-dataset-for-brtx-100-showing-sustained-pain-and-functional-improvements-in-chronic-lumbar-disc-disease

05/07/2026

announces expanded blinded data from its fully enrolled Phase 2 evaluating BRTX-100, our autologous hypoxic-cultured mesenchymal stem cell therapy for the treatment of chronic lumbar disc disease.

The data demonstrated sustained improvements in both pain and function among patients with chronic lumbar disc disease and was presented yesterday at the Annual Meeting by our Chief Scientist, Francisco Silva.

Check out some highlights from Francisco’s presentation and learn more about the latest on BRTX-100 in our press release: bit.ly/4no20l6